In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

RespireRx Pharmaceuticals Inc.

http://www.respirerx.com

Latest From RespireRx Pharmaceuticals Inc.

Finance Watch: Evotec, LianBio, IO Biotech Launch IPOs, Bringing US Total To 101

Public Company Edition: Blade will merge with a special purpose acquisition corporation to go public, Bluebird spins out 2seventy with $442m in cash and Compass raises $125m in a move to the Nasdaq. 

Financing Innovation

EyeGene: EG-COVID Will Be Starting Point For Other mRNA Vaccines

EyeGene R&D head talks to Scrip at CPhI Korea about the development of its COVID-19 vaccine candidate EG-COVID, potential challenges in clinical trials and positioning and the over-riding importance of validating a viable mRNA platform.

South Korea Coronavirus COVID-19

Asia Deal Watch: Hansoh Teams Up With OliX On SIRNA Therapies

Among other Asia deals, Takeda adds to pair of recent gene therapy tie-ups with a CNS-focused cell therapy partnership with Immusoft; earlier it licensed ex-US rights to JCR’s Hunter syndrome drug.

Deal Watch Business Strategies

Apnimed Moves Closer To Phase III With Sleep Apnea Drug

Apnimed is going to conduct one more Phase II study in sleep apnea, mainly to assess subjective endpoint questionnaires, and then hopes to launch a Phase III program by autumn of 2022.

Clinical Trials Drug Approval Standards
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Cortex Pharmaceuticals, Inc.
    • Pier Pharmaceuticals, Inc.
UsernamePublicRestriction

Register